Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit

On December 8, 2021 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs reported its participation in the Targeted Radiopharmaceuticals Summit being held virtually December 7 – 9, 2021 (Press release, Actinium Pharmaceuticals, DEC 8, 2021, View Source [SID1234596585]). The Targeted Radiopharmaceuticals Summit brings together experts and thought leaders in the field with the goal to achieve meaningful clinical efficacy with theragnostic radionuclide therapies in a mono and combinatorial setting & deliver a robust, cGMP compliant manufacturing supply chain. Representatives from Actinium’s R&D and Clinical Development teams have been invited to participate as expert speakers in two panel presentations during the Targeted Radiopharmaceuticals Summit. The panel details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Panel: Review of the Last 12 Months of Development of Alpha Emitting Therapies

Session: Next Generation Alpha Emitter Based Therapeutics

Actinium Expert Speaker: Helen Kotanides, Ph.D., Vice President, Translational Research and Preclinical Development

Date and Time: December 9, 2021, 5:30 pm CET, 11:30 am EST

Panel: High Dose – Low Dose Therapeutic Strategy: Tailoring the Dose of Radiopharmaceuticals for Opportunity and Outcomes

Session: Optimizing Treatment Regimens

Actinium Expert Speaker: Mary Chen, M.D., Ph.D., Vice President, Clinical Development

Date and Time: December 9, 2021, 6:30 pm CET, 12:30 pm EST

Learn more about the Targeted Radiopharmaceuticals Summit at www.targeted-radiopharma.com.